Atara Biotherapeutics, Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 480 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Atara Biotherapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ATRA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Atara Biotherapeutics stock price (NASDAQ: ATRA)Use our graph to track the performance of ATRA stocks over time.
Atara Biotherapeutics shares at a glance
|Latest market close||$13.56|
|52-week range||$11.33 - $26.10|
|50-day moving average||$14.43|
|200-day moving average||$15.46|
|Wall St. target price||$35.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.07|
Buy Atara Biotherapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atara Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atara Biotherapeutics price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-14.82%|
|3 months (2021-04-30)||-3.56%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Atara Biotherapeutics financials
|Revenue TTM||$3.6 million|
|Gross profit TTM||$0|
|Return on assets TTM||-47.13%|
|Return on equity TTM||-95.56%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Shorting Atara Biotherapeutics shares
There are currently 12.1 million Atara Biotherapeutics shares held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 3.7% up from 11.7 million last month.
There are a few different ways that this level of interest in shorting Atara Biotherapeutics shares can be evaluated.
Atara Biotherapeutics's "short interest ratio" (SIR)
Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics shares currently shorted divided by the average quantity of Atara Biotherapeutics shares traded daily (recently around 916927.23823976). Atara Biotherapeutics's SIR currently stands at 13.18. In other words for every 100,000 Atara Biotherapeutics shares traded daily on the market, roughly 13180 shares are currently held short.
However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics shares, or, against the total number of tradable Atara Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Atara Biotherapeutics shares in existence, roughly 140 shares are currently held short) or 0.1979% of the tradable shares (for every 100,000 tradable Atara Biotherapeutics shares, roughly 198 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atara Biotherapeutics.
Find out more about how you can short Atara Biotherapeutics stock.
Atara Biotherapeutics share dividends
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.
Atara Biotherapeutics share price volatility
Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $11.33 up to $26.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.4363. This would suggest that Atara Biotherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Atara Biotherapeutics overview
Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.
Stocks similar to Atara Biotherapeutics
Atara Biotherapeutics in the news
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Trellus Management Company, LLC Buys Vertex Energy Inc, Genius Sports, Coupang Inc, Sells dMY Technology Group Inc II, MercadoLibre Inc, Amazon.com Inc
Short Report: Fisker short interest hits three-week high of 25%
Frequently asked questionsWhat percentage of Atara Biotherapeutics is owned by insiders or institutions?
Currently 0.594% of Atara Biotherapeutics shares are held by insiders and 106.828% by institutions. How many people work for Atara Biotherapeutics?
Latest data suggests 480 work at Atara Biotherapeutics. When does the fiscal year end for Atara Biotherapeutics?
Atara Biotherapeutics's fiscal year ends in December. Where is Atara Biotherapeutics based?
Atara Biotherapeutics's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080 What is Atara Biotherapeutics's ISIN number?
Atara Biotherapeutics's international securities identification number is: US0465131078 What is Atara Biotherapeutics's CUSIP number?
Atara Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 046513107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert